Eligibility for CAR T‐cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL

D. Smith, Stephen; Reddy, Prathima; Sokolova, Alexandra; A. Chow, Victor; C. Lynch, Ryan; A. Shadman, Mazyar; G. Till, Brian; R. Shustov, Andrei; H. Warren, Edus; S. Ujjani, Chaitra; P. Menon, Manoj; D. Tseng, Yolanda; K. Gopal, Ajay

doi:10.1002/ajh.25411

Public

Eligibility for CAR T‐cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL

Shared by NobleBlocks on Apr 1, 2019 • 12:00 AM UTC

Authors:

Stephen D. Smith

Prathima Reddy

Alexandra O. Sokolova

Abstract

Chimeric antigen receptor T-cell (CAR T-cell) therapy with axicabtagene ciloleucel, approved for chemorefractory diffuse large B-cell lymphoma, showed promising efficacy in the ZUMA-1 trial. However, eligibility criteria for ZUMA-1 was stringent. Applying these criteria to a cohort of DLBCL patients...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!